712 related articles for article (PubMed ID: 18929127)
41. Neuroprotection in glaucoma: recent and future directions.
Danesh-Meyer HV
Curr Opin Ophthalmol; 2011 Mar; 22(2):78-86. PubMed ID: 21252670
[TBL] [Abstract][Full Text] [Related]
42. [Contemporary possibilities and perspectives in the treatment of glaucoma].
Czepita D
Ann Acad Med Stetin; 2005; 51(1):27-31. PubMed ID: 16496599
[TBL] [Abstract][Full Text] [Related]
43. Multiple roles for the endocannabinoid system during the earliest stages of life: pre- and postnatal development.
Fride E
J Neuroendocrinol; 2008 May; 20 Suppl 1():75-81. PubMed ID: 18426504
[TBL] [Abstract][Full Text] [Related]
44. Cannabinoids in the treatment of glaucoma.
Järvinen T; Pate DW; Laine K
Pharmacol Ther; 2002 Aug; 95(2):203-20. PubMed ID: 12182967
[TBL] [Abstract][Full Text] [Related]
45. 5-Hydroxytryptamine1A agonists: potential use in glaucoma. Evidence from animal studies.
Osborne NN; Wood JP; Melena J; Chao HM; Nash MS; Bron AJ; Chidlow G
Eye (Lond); 2000 Jun; 14 ( Pt 3B)():454-63. PubMed ID: 11026974
[TBL] [Abstract][Full Text] [Related]
46. The endocannabinoid system as a target for the treatment of neuronal damage.
Fernández-Ruiz J; García C; Sagredo O; Gómez-Ruiz M; de Lago E
Expert Opin Ther Targets; 2010 Apr; 14(4):387-404. PubMed ID: 20230193
[TBL] [Abstract][Full Text] [Related]
47. New approaches to antiglaucoma therapy.
Sugrue MF
J Med Chem; 1997 Aug; 40(18):2793-809. PubMed ID: 9288160
[No Abstract] [Full Text] [Related]
48. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma.
Tsai JC; Song BJ; Wu L; Forbes M
J Glaucoma; 2007 Sep; 16(6):567-71. PubMed ID: 17873720
[TBL] [Abstract][Full Text] [Related]
49. [Influence of prostaglandins on aqueous humour dynamics and intraocular pressure].
Raber T
Klin Monbl Augenheilkd; 2005 Oct; 222(10):802-6. PubMed ID: 16240273
[TBL] [Abstract][Full Text] [Related]
50. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia.
Müller-Vahl KR; Emrich HM
Expert Rev Neurother; 2008 Jul; 8(7):1037-48. PubMed ID: 18590475
[TBL] [Abstract][Full Text] [Related]
51. Discovery of novel inhibitors for the treatment of glaucoma.
Cholkar K; Trinh HM; Pal D; Mitra AK
Expert Opin Drug Discov; 2015 Mar; 10(3):293-313. PubMed ID: 25575654
[TBL] [Abstract][Full Text] [Related]
52. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma.
Neufeld AH
Brain Res Bull; 2004 Feb; 62(6):455-9. PubMed ID: 15036557
[TBL] [Abstract][Full Text] [Related]
53. Inherited glaucoma in DBA/2J mice: pertinent disease features for studying the neurodegeneration.
Libby RT; Anderson MG; Pang IH; Robinson ZH; Savinova OV; Cosma IM; Snow A; Wilson LA; Smith RS; Clark AF; John SW
Vis Neurosci; 2005; 22(5):637-48. PubMed ID: 16332275
[TBL] [Abstract][Full Text] [Related]
54. Cannabinoids and appetite: food craving and food pleasure.
Kirkham TC
Int Rev Psychiatry; 2009 Apr; 21(2):163-71. PubMed ID: 19367510
[TBL] [Abstract][Full Text] [Related]
55. Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation.
Schwartz M; London A
Prog Brain Res; 2008; 173():375-84. PubMed ID: 18929122
[TBL] [Abstract][Full Text] [Related]
56. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?
Croxford JL; Yamamura T
J Neuroimmunol; 2005 Sep; 166(1-2):3-18. PubMed ID: 16023222
[TBL] [Abstract][Full Text] [Related]
57. Pathophysiology of glaucoma and continuous measurements of intraocular pressure.
Sit AJ; Liu JH
Mol Cell Biomech; 2009 Mar; 6(1):57-69. PubMed ID: 19382536
[TBL] [Abstract][Full Text] [Related]
58. Cannabinoid receptors: where they are and what they do.
Mackie K
J Neuroendocrinol; 2008 May; 20 Suppl 1():10-4. PubMed ID: 18426493
[TBL] [Abstract][Full Text] [Related]
59. Targets of Neuroprotection in Glaucoma.
He S; Stankowska DL; Ellis DZ; Krishnamoorthy RR; Yorio T
J Ocul Pharmacol Ther; 2018; 34(1-2):85-106. PubMed ID: 28820649
[TBL] [Abstract][Full Text] [Related]
60. The inflow and outflow of anti-glaucoma drugs.
Woodward DF; Gil DW
Trends Pharmacol Sci; 2004 May; 25(5):238-41. PubMed ID: 15120486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
